AbbVie, Roche Claim Important Win For Venetoclax In CLL
This article was originally published in Scrip
Executive Summary
Partners AbbVie and Roche's Genentech scored an important win for their B-cell lymphoma-2 (BCL-2) inhibitor venetoclax in a Phase II clinical trial that met the study's primary endpoint in hard-to-treat chronic lymphocytic leukemia (CLL) patients, setting the stage for potential accelerated approval.